2 assets in Cerebellar Liponeurocytoma

Therapeutic assets addressing Cerebellar Liponeurocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Cerebellar Liponeurocytoma	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Cerebellar Liponeurocytoma	Novartis Pharmaceuticals	P4	BB (65)